Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Go Back to All Clinical Trials

Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Brief description of study

The purpose of the trial is to determine the safety and efficacy of the pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus androgen deprivation therapy (ADT) in participants with metastatic hormone-sensitive prostate cancer (mHSPC). We want to know if one treatment is superior to another when treating participants with metastatic hormone-sensitive prostate cancer.

Clinical Study Identifier: s19-01532

ClinicalTrials.gov Identifier: NCT04191096

Principal Investigator: David R. Wise.

Other Investigators: Victor Ricardo Adorno Febles, Arjun Vasant Balar, Daniel C Cho.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies